Trichostatin A (TSA)

Catalog No.S1045

Trichostatin A (TSA) Chemical Structure

Molecular Weight(MW): 302.4

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.

Size Price Stock Quantity  
USD 247 In stock
USD 447 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

6 Customer Reviews

  • Gck expression in WT primary hepatocytes transduced with FOXO1 and KR-FOXO1 adenoviruses in the presence or absence of trichostatinA (TSA).

    Cell, 2017, 171(4):824-835.e18. Trichostatin A (TSA) purchased from Selleck.

    Effect of TSA, SAHA and silibinin alone and in combination on left panel: IF staining for p-histone H3 Ser 10 and p-MPM-2 Ser /Thr positive cells and a-tubulin for mitotic spindle and DAPI as nuclear stain in H1299 cells. Right panel: % positive p-histone H3 Ser 10 mitotic cells and expression of p-MPM-2 Ser /Thr protein levels in H1299 cells.

    Epigenetics 2012 7(10):1161-72. Trichostatin A (TSA) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

  • (B) The mRNA level of PRRT2 in the presence of different concentrations of DAC and TSA.

    Biochem Biophys Res Commun, 2017, 485(2):454-460. Trichostatin A (TSA) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM TSA was added.

     

     

    2010 Dr. Zhang of Tianjin Medical University. Trichostatin A (TSA) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Targets
HDAC [1]
(Cell-free assay)
~1.8 nM
In vitro

Trichostatin A inhibits the proliferation of eight breast carcinoma cell lines including MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3 with mean IC50 of 124.4 nM (range, 26.4-308.1 nM), with more potency against cell lines that express ERα than the ERα-negative cell lines. Trichostatin A inhibits HDAC activity similarly in all the breast cancer cell lines with mean IC50 of 2.4 nM (range, 0.6-2.6 nM), and results in pronounced histone H4 hyperacetylation. [1] Unlike Trapoxin (TPX) and Chlamydocin which potently inhibit HDAC1 or HDAC4 but not HDAC6, Trichostatin A inhibits these HDACs to a similar extent with IC50 of 6 nM, 38 nM, and 8.6 nM, respectively. [2] Trichostatin A (100 ng/mL) treatment induces the expression of transforming growth factor β type II receptor (TβRII) in MIA PaCa-2 cells through the recruitment of p300 and PCAF into a Sp1-NF-Y HDAC complex that binds the DNA element of TβRII promoter, which is associated with a concomitant acetylation of Sp1 and an overall decrease in the amount of HDAC associated with the complex. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK 293 MnXrSpVv[3Srb36gRZN{[Xl? MlXpNE44|ryP MVSyOIg> M1jp[4V1cGGwb3y= NFG2OoNmdmijbnPld{BGVmGFIHHj[ZR6dGG2aX;uJIFv\CCrbnPy[YF{\XNiRV7hR{Bi[nWwZHHuZ4UhcW5idHjlJJRwfGGuIHPlcIwhdHm|YYTlJIFv\CCjdDD0bIUh[2WubDDzeZJn[WOn MUWyOVc5PzB5OR?=
TE13 NGi0c25HfW6ldHnvckBCe3OjeR?= MljrNE4{|ryP MlqzNlRp MWr1dE1z\We3bHH0[ZMhWkGVU1[1RUBt\X[nbB?= MX[yOVU4QTZ4NR?=
TE13 MluyRZBweHSxc3nzJGF{e2G7 MmnGNE4{|ryP MoT0NlRp MV;pcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9v NWjRS|FzOjV3N{m2OlU>
MEFs NX3hWZB6TnWwY4Tpc44hSXO|YYm= MkK3Oe69VQ>? MVixOog> NIThb|FqdmO{ZXHz[ZMhfGinIFXQSWMh[XS2YXPocYVvfCxiVHnyJIRmdGm4ZYL5JIFv\CC2aHWg[YZncWOrZX7jfUBw\iCyZXTld5RidCCob4LtZZRqd25? M1Ls[VI2PDh{NkO0
SW480  MWPGeY5kfGmxbjDBd5NigQ>? M{H1blAvOc7:TR?= NXrZdFE4PDiq M2HPVGROW09? NWLSSY81emW4ZYLz[ZMhTU2W M{HCbVI2PDN2OUm3
PC3  M4jxZmZ2dmO2aX;uJGF{e2G7 M{\1NlAvOc7:TR?= MVe0PIg> NHHMVIFFVVOR MVPy[ZZmenOnczDFUXQ> MoHGNlU1OzR7OUe=
SW480  MkfKSpVv[3Srb36gRZN{[Xl? MmD2NE4y|ryP Mm\hOFhp NEXCNllFVVOR M13k[YF1fGWwdXH0[ZMhcW64YYPpc44h[W6mIH3p[5JifGmxbh?= M2LRNFI2PDN2OUm3
PC3  NXXKe4YzTnWwY4Tpc44hSXO|YYm= M1nmcFAvOc7:TR?= MUW0PIg> Mk[ySG1UVw>? NYrVfW13[XS2ZX71ZZRmeyCrbo\hd4lwdiCjbnSgcYloemG2aX;u NWLyUG9LOjV2M{S5PVc>
SW480  MoPrSpVv[3Srb36gRZN{[Xl? NX74dJh6OC5zzszN Mn3rOFhp MmTmSG1UVw>? NXW0cGlDcW6mdXPld{BqdmO{ZXHz[UBw\iCKRFHDNUBidmRiSFTBR|Ihd25iU3z1[{Bo\W6nczDwdo9ud3Snch?= NYLZfI11OjV2M{S5PVc>
PC3  MXXGeY5kfGmxbjDBd5NigQ>? MnX6NE4y|ryP MV20PIg> NVuyTVROTE2VTx?= M3vTfYlv\HWlZYOgbY5kemWjc3Wgc4YhUESDQ{GgZY5lKEiGQVOyJI9vKFOudXeg[4Vv\XNicILvcY91\XJ? NYrpUnd1OjV2M{S5PVc>
A431 M1rQWGFxd3C2b4Ppd{BCe3OjeR?= NULTeXMyOi9zMD:1NE8yODCwTR?= NEX3VXo1QGh? MU\EUXNQ M4\1b4lvcGmkaYTzJJRp\SClZXzsJIdzd3e2aB?= MWOyOVM4OTB4OR?=
A431 MnX6SpVv[3Srb36gRZN{[Xl? NULPXY1VPTCwTR?= M2fEUlIwPi9zMj:yOIg> Ml70SG1UVw>? NFjYNIdi[3SrdnH0[ZMheDJzIHHu[EBqdmirYnn0d{BCXEZ|IHX4dJJme3Orb36= MkL6NlU{PzFyNkm=
MDA-MB-231 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\WNE03ODCwTR?= MXqyOIg> MlLzSG1UVw>? NVX2U3BpUUN3MDDv[kAyODCwTR?= NH65bmszPTF7MkeyNS=>
MCF7 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTQUWF4OC14MEDuUS=> M4nEdlI1cA>? MV3EUXNQ NV;EWol[UUN3MDDv[kA4PW6P MoC1NlUyQTJ5MkG=
SKOV-3 NUT1O|NqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PESFEuOTEQvF2= MnXBNlRp NY\GOno4TE2VTx?= NFHXXXNKSzVyIH;mJFUvPs7:TR?= MXGyOVE3QTR7MR?=
A549 Mn;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\ONU0yOM7:TR?= NITx[mEzPGh? M3ztPWROW09? MV;JR|UxKG:oIEOuNu69VQ>? NWnJeJNMOjVzNkm0PVE>
SKOV-3 NVvJO4E2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLBcWcxNjFvMd88US=> NHrxe|k1QGh? NYfPXY1GTE2VTx?= MXzJR|UxKG:oIECuO:69VQ>? NFHiXWMzPTF4OUS5NS=>
A549 MmnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVWwMlEuOc7:TR?= NYLuU493PDiq NHvOZ5JFVVOR Mk\tTWM2OCCxZjCwMlI5|ryP MorvNlUyPjl2OUG=
SKOV-3 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPuU4xKOC5yMT2wMlnPxE1? M3fwOFczcA>? MkDoSG1UVw>? NETOS4NKSzVyIH;mJFAvOzMQvF2= MUWyOVE3QTR7MR?=
A549 MkHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUGwMlAyNTBwOd88US=> M1jPWlczcA>? NUPiUWtXTE2VTx?= M4TWOWlEPTBib3[gNE4xPs7:TR?= NVTIU3ZPOjVzNkm0PVE>
HeLa M3LPRWZ2dmO2aX;uJGF{e2G7 NXzJWoI3OjVybl2= M1;yelE3cA>? MYPEUXNQ NFTrdmpqdmO{ZXHz[ZMhS1mSMVGxJI1TVkFiZYjwdoV{e2mxbtMg NHy0SGgzPTFzNk[4PC=>
CNE2 M{LtSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXIU41OOTByLU[wNI5O NGTyblczPC92OD:3Nog> NEm2N2RqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckBqdiCjIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NWrId5A4OjR7Nkm5NFE>
PC3 NFjrWYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTxVnU2OTByLUGwNFBvVQ>? NFjTPY0zPGh? NEH4ZmVKSzVyIH;mJFMxOG6P MYKyOFg2PDZ3OB?=
LNCaP MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXmxNFAuOTByMH7N MmLsNlRp NE[ySXhKSzVyIH;mJFMxOG6P M1Xi[lI1QDV2NkW4
HeLa  NUPTUFVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vGZVLPxE1? MX:0PIg> MUPk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliYXLveZQhOjVn NVLHZoQ6OjR6NE[xN|U>
HMEC-1  NGfKPXpHfW6ldHnvckBCe3OjeR?= MknTN|Axdk1? MVKyOIg> NXns[404cW6lcnXhd4V{KGW6cILld5Nqd25ib3dCpHZGT0[UM9MgcXJPSQ>? NWHwTnlmOjR5MUC2N|E>
HeLa MnrvSpVv[3Srb36gRZN{[Xl? NFPsV3gydU1? NHr1Z5MxNjWq NXW5XHpH[WKxbHnzbIV{KHSqZTD0c5RidCCKRFHDJIFkfGm4aYT5 M{DQbFI1PzB5NEe0
ACP02 NV;tV4VWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWq2fWw5OjVyL{O1NE82ODCwTR?= M2O3VlI1cA>? NUP3e5FL\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JI9nKGGycILvfIlu[XSnbImgO|DDqCViYYSgNlUxyqCwTR?= M2q2WFI1PjZ6NUS3
ACP03 NXnxU2xKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrTNlUxNzN3MD:1NFBvVQ>? MVyyOIg> NYLjO4dG\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JI9nKGGycILvfIlu[XSnbImgO|DDqCViYYSgNlUxyqCwTR?= MVOyOFY3QDV2Nx?=
U87 GBM MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUWxNFAwOzByL{WwNEBvVQ>? NVi3Rlc2PzJiaB?= NUHLfHdbOTByJTDleIhidm:u Mn7JdoVlfWOnczDt[YFvKGOnbHygcpVu[mW{IHL5JFMyNCB3NDygZY5lKDV6wrCl NXLGT|d4OjR2NkS4OFE>
U87 GBM NX7jdHpLTnWwY4Tpc44hSXO|YYm= MUWxNFAwPTByIF7t NFLWPII1QCCq NV61bppzOTByJTDleIhidm:u NUTjdW9mUW6mdXPld{BU\W6nc3PlcoNmNUyra3WgRYx1\XKjdHnvcpMhcW5iToXjcIVieiCPb4LwbI9td2e7 NHLrNWczPDR4NEi0NS=>
RPE NYGyeINwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XxPVAvOi9yLkSvNE45NzFizszN Mni5NlQwPDhxN{KgbC=> Mli4SG1UVw>? Mn[3bY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36gZpkh[2WubDDjfYNt\SCjcoLld5Q> MUOyOFQ2PjZyMh?=
HT29  MnjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITQeoQyQDBibl2= NIK0PXY4OiCq M1jxcmlEPTBib3[gNVgxKG6P NXfhWFFIOjR|NkiyOlU>
hMSCs NF3mO|lHfW6ldHnvckBCe3OjeR?= NXjMNnF{Pi5{NTDuUS=> MknRNlQhcA>? MXXEUXNQ M{n4SZN1[WKrbHn6[ZMhUGm|dH;u[UBC[2W2eXzheIlwdiCjbnSgeIhmKEW6cILld5Nqd25ib3[gVIx2emmyb4TlcpQhT2WwZYO= M3f4dVI1OzF{M{W2
Huh7  MmK2SpVv[3Srb36gRZN{[Xl? NH\G[I4xNjFxMD61M|EvOCEQvF2= NE\hbWMzPGh? M{D3XZN2eHC{ZYPz[ZMhYVSKRFOyJIdmdmViZYjwdoV{e2mxbh?= MkLVNlQzPjl4N{K=
SKOV3 M{TmXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIG2[ncxNjB3LUKg{txO NWPsT|AzOTBxMkSvOFghcA>? NFK2RYtFVVOR M1HaO41m\GmjdHXzJIdzd3e2aDDhdpJme3RiaX6gZUBkd26lZX70doF1cW:wLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ M4jBd|I1OjJ|OECx
A2780 MnfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonVNE4xPS1{IN88US=> NWfYV4NUOTBxMkSvOFghcA>? NHTXOZpFVVOR NXPCOYxzdWWmaXH0[ZMh\3Kxd4ToJIFzemW|dDDpckBiKGOxbnPlcpRz[XSrb36tJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= MnzhNlQzOjN6MEG=
SRA01/04  M4PZZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TFcFAvOiEQvF2= NGDDR3c1QCCq NGC4cFZFVVOR MUPzeZBxemW|c3XzJINmdGxicILvcIln\XKjdHnvckB1cHKxdXfoJJN2eHC{ZYPzbY5oKHSqZTDQTVNMN0GtdDygdFM5VUGSSzDhcoQhTVKNMT:yJJNq\26jbHnu[{Bx[XSqd3H5dy=> NHHaVZIzPDF3N{i3PC=>
HLEB3 M3LDdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHH5dJcxNjJizszN M{P0blQ5KGh? MWDEUXNQ NIHWboZ{fXCycnXzd4V{KGOnbHygdJJwdGmoZYLheIlwdiC2aILveYdpKHO3cIDy[ZN{cW6pIITo[UBRUTONL1HreEwheDN6TVHQT{BidmRiRWLLNU8zKHOrZ37hcIlv\yCyYYToe4F6ew>? NVPoUG1IOjRzNUe4O|g>
SRA01/04  M4C0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVGwMlQwOC56IN88US=> NHzkU2k1QCCq NH3aVmNFVVOR NWPoRZZEcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NVfufFhWOjRzNUe4O|g>
HLEB3 M2W2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPNZoZ2OC52L{CuPEDPxE1? MnjMOFghcA>? MVjEUXNQ MX;pcoR2[2W|IHPlcIwh[XCxcITvd4l{ MWmyOFE2Pzh5OB?=
HCT116 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYmwMlIh|ryP NFrpZlAyOiCq Mmfl[Y5p[W6lZYOgZ4VtdCCjcH;weI9{cXNiaX7keYNm\CCkeTDyZYRq[XSrb36= M4L1U|I1OTJ{MkOx
CA46 NY\QbHU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUP2RXo5Oy94L{GyM|I1NzR6IH7N MX[0PEBp NFzleHVqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHH0JFI1KGGwZDC0PEBvVcLi NWfu[VRoOjRyNkS5OVE>
PMNs M325V2Z2dmO2aX;uJGF{e2G7 NFPUe|g{OCCwTR?= Mlv2OFghcA>? MojRbY5pcWKrdIOg[YZn\XKxY4n0c5NqeyxiSFTBR{Bi[3Srdnn0fUBidmRiUnHjJIFkfGm4aYT5 M37FT|I{QTh6NkG3
H1299 M1K5SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jBRlHDqM7:TdMg NVy3RWJKOjRxNEivO|IhcA>? M4\QN4V1cGGwb3y= NYjPR4I{cW6lcnXhd4V{KGOnbHyg[IVifGhiYX\0[ZIhOjSq M3r6Z|I{QTF4NkC5
A549 NV;mOHd[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYWwMlI2NzBwNT:xJO69VQ>? MVyyOE81QC95MjDo NYDyclZJ\XSqYX7vcC=> M1myXolvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDpckBkd26lZX70doF1cW:wIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? MXmyN|g3Pzl7MR?=
H1299 MmP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYOwMlI2NzBwNT:xJO69VQ>? NXPJRotjOjRxNEivO|IhcA>? Mnuz[ZRp[W6xbB?= MX3pcohq[mm2czD0bIUh[2WubDDndo94fGhiaX6gZ49v[2WwdILheIlwdiCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz NWjlfnJTOjN6Nke5PVE>
A549 MljGRZBweHSxc3nzJGF{e2G7 MX2wMlUwOSEQvF2= NHjvO|M1QCCq NGPqXo9mfGijbn;s M1jOT4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MUOyN|g3Pzl7MR?=
H1299 NYn4TppSSXCxcITvd4l{KEG|c3H5 M{jSb|AvPS9zIN88US=> MlrIOFghcA>? Mo\h[ZRp[W6xbB?= NHfrRVlqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NHzw[WQzOzh4N{m5NS=>
SUM149PT M2LnVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2iySVIwPy53L{GwJO69VQ>? NHrVT4o1QCCq MlvTSG1UVw>? MmXqbY5lfWOnczDj[YxtKGSnYYToJIF1KDJizszNJIlve2Wwc3n0bZZmdHl? MojrNlM4QTJ4M{i=
SUM190PT NGP0e3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLxOVAwOTByL{K1NEBvVQ>? M1fIfFQ5KGh? NH\nbYJFVVOR NVHQNmhFcW6mdXPld{Bk\WyuIHTlZZRpKGG2IEWwJI5OKHOnboPpeIl3\Wy7 M2XXdFI{Pzl{NkO4
HCT1 M4XlT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4O4XlAvOi9zLkCvOU4xKM7:TR?= MUexNk8zPC9|Nj:0PEBp MVPpcoR2[2W|IHPlcIwh\GWjdHigbY4h[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= NHWyVW8zOzd5MECwNC=>
Lovo MmPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLpdG9SOC5{L{GuNE82NjBizszN NWTubYFZOTJxMkSvN|YwPDhiaB?= NW\XdnlRcW6mdXPld{Bk\WyuIHTlZZRpKGmwIHPvcoNmdnS{YYTpc44uKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> NVfBV3NEOjN5N{CwNFA>
AGS NWjyVoliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LY[FAvODF3LUGg{txO MXy3NkBp M4K3Oolv\HWlZYOgZ4VtdCCmZXH0bEBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5 NEXKTIkzOzd2NUCyOC=>
Huh7 NWPUUG1CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWSxJO69VQ>? MmDFNlQhcA>? NFrVXJhFVVOR MnTUdoVlfWOnczDhZo92fCB{MDWgeoli[mmuaYT5xsA> M2T1eFI{PjR|OUOz
ECC1 M2PwXmZ2dmO2aX;uJGF{e2G7 Ml\2OVAxKG6P Mo[zOUBl MWPEUXNQ NXvGTlJHcW6mdXPld{BNOUODTdMg[ZhxemW|c3nvckBkdy22cnXheI1mdnRid3n0bEA2NUG8YVO= NWnQZWlJOjN3M{C3Olk>
HEC1A NXftSI5VTnWwY4Tpc44hSXO|YYm= NUHndo51PTByIH7N MY[1JIQ> MmXqSG1UVw>? NELKPGVqdmS3Y3XzJGwyS0GPwrDlfJBz\XO|aX;uJINwNXS{ZXH0cYVvfCC5aYToJFUuSXqjQx?= NYWyb4d4OjN3M{C3Olk>
EN1 MoDSSpVv[3Srb36gRZN{[Xl? NYrUfZNVPTByIH7N NIfTZlc2KGR? NHO0bJpFVVOR MVrpcoR2[2W|IFyxR2FOyqCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEWtRZpiSw>? M1LCOVI{PTNyN{[5
MFE296 MVTGeY5kfGmxbjDBd5NigQ>? MmfPOVAxKG6P MXS1JIQ> NXPINlNyTE2VTx?= MYrpcoR2[2W|IFyxR2FOyqCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEWtRZpiSw>? M1PUS|I{PTNyN{[5
HASMCs MXPGeY5kfGmxbjDBd5NigQ>? NFTtXmcxNTVyMDDuUS=> NH;XNIE3KGR? NVPiXoFz\G:5bj3y[Yd2dGG2ZYOgeIhmKGW6cILld5Nqd25ib3[gTGFFSyCjbnSgZ4VtdCC4aXHibYxqfHl? MVyyN|UyQDR4Nx?=
U373 MkHlSpVv[3Srb36gRZN{[Xl? M3KxXFAvOjVxMD61M|Eh|ryP M4ruWFI1KGh? MXLpcoNz\WG|ZYOgVHIuSiCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEXBfoFlSw>? Ml7iNlM1PzRzN{G=
ARN8  MYTGeY5kfGmxbjDBd5NigQ>? MleyNE4xPS1{IN88US=> NVO3OVRKOjRiaB?= NHnMPHZz\WS3Y3XzJJRp\SCrbnT1Z5Rqd25ib3[gdFU{NWSncHXu[IVvfCCpZX7ld{BjgSCQdYTsbY4uOw>? M{jUPVI{PDdyNUSw
MCF7 MV;GeY5kfGmxbjDBd5NigQ>? NGfwRmsxNjB3LUKg{txO NX;6VoRVOjRiaB?= MkHQdoVlfWOnczD0bIUhcW6mdXP0bY9vKG:oIIC1N{1l\XCnbnTlcpQh\2WwZYOgZpkhVnW2bHnuMVM> NVfofot7OjN2N{C1OFA>
H1299  NGLmO2FHfW6ldHnvckBCe3OjeR?= NIT4U5YxNjN|4pETNeKhyrWP NH\yOJAzPC92ODDo NWX2Nm9QTE2VTx?= NHrTNHJqdmO{ZXHz[ZMhTS2lYXTo[ZJqdiCycn;0[YlvKGyndnXsd{Bld3OnIHTldIVv\GWwdHz5 MXiyN|Q3OTl5NR?=
H1299 MonoSpVv[3Srb36gRZN{[Xl? MYWwMlUh|ryP M2PSdFQ5KGh? M{jiSWROW09? NFvPOXlqdmirYnn0d{B1cGVibXnndoF1d3K7IIDveIVvfGmjbDDjc41jcW6nIIfpeIghe2muaXLpcolv NHvLPHkzOzR4MUm3OS=>
H1299 NG\pd3lHfW6ldHnvckBCe3OjeR?= NIXESmgxNjVizszN MXq0PEBp NHzHNmpFVVOR MmjPbY5pcWKrdIOgeIhmKGmwdnHzbZZmdmW|c9MgJINwdWKrbnWge4l1cCC|aXzpZolvcW5? NG\VOoMzOzR4MUm3OS=>
MG-63  NGjOPGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILVR4UxNjNizszN MlvINVIuQTZiaB?= NWHIZZpJTE2VTx?= NHrvdopqdmirYnn0d{B1cGViY3XscEBoem:5dHigZ48ufHKnYYTt[Y51KHerdHigcYV1\m:{bXnu NWq3bJFwOjN2NUG4NVc>
LM8 NUTneIlVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHINE4{KM7:TR?= M2\oVFEzNTl4IHi= M1:5dmROW09? NVL4TG1pcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJINwNXS{ZXH0cYVvfCC5aYToJI1mfG[xcn3pci=> M2rTOFI{PDVzOEG3
K562 M3iyUmZ2dmO2aX;uJGF{e2G7 MX2wMlUh|ryP NIDNSYEzPCCq MXfleIhidm:u NFSwc49l\WO{ZXHz[ZMhfGinIHXufplu\SCjY4Tpeol1gSCxZjDISGFEeyClbz30doVifG2nboSge4l1cCCldYLjeY1qdg>? NXjzOJNwOjN2M{C5OVc>
HEL M{PQNWZ2dmO2aX;uJGF{e2G7 NHfIb4IxNjVizszN MoLVNlQhcA>? Mnn3[ZRp[W6xbB?= NF;Ec4Fl\WO{ZXHz[ZMhfGinIHXufplu\SCjY4Tpeol1gSCxZjDISGFEeyClbz30doVifG2nboSge4l1cCCldYLjeY1qdg>? MlfjNlM1OzB7NUe=
HL60 NVy2VXAxSXCxcITvd4l{KEG|c3H5 MWSxJO69VQ>? Mn\BNlQhcA>? MYHpcoR2[2W|wrDj[YxtKGSnYYTo NF3QT3ozOzRyMEWxPS=>
KG1 MmHFRZBweHSxc3nzJGF{e2G7 MV[xJO69VQ>? NFH2NmczPCCq M3H0fIlv\HWlZYRCpINmdGxiZHXheIg> MoPqNlM1ODB3MUm=
Kazumi MUXBdI9xfG:|aYOgRZN{[Xl? MoLNNUDPxE1? MWOyOEBp MUPpcoR2[2W|wrDj[YxtKGSnYYTo NXrURlZ6OjN2MEC1NVk>
K562 Mn\MRZBweHSxc3nzJGF{e2G7 M1XsUlEh|ryP MkG1NlQhcA>? M1HBUolv\HWlZYRCpINmdGxiZHXheIg> M2HYbFI{PDByNUG5
THP1 MV3BdI9xfG:|aYOgRZN{[Xl? NGDLXoQyKM7:TR?= M2CxSFI1KGh? M1XBPYlv\HWlZYRCpINmdGxiZHXheIg> NWPE[Yt7OjN2MEC1NVk>
SH-SY5Y NHna[GJHfW6ldHnvckBCe3OjeR?= NVHNfJNvOjVyIH7N NUjKTlBLOTZiaB?= MVrjbIFv\2W|IHX4dJJme3Orb36gdIF1fGW{bjDv[kBo\W6nczDpcpZwdH[nZDDpckBkcG:uZYP0[ZJwdCC|eX70bIV{cXNuIIXweIFs\SCjbnSg[YZndHW6 NIW0N20zOzN{NkSyNi=>
HEK293 MkjGSpVv[3Srb36gRZN{[Xl? M3\EV|EhyrWPwrC= MlfXNVghcMLi MnzPbY5pcWKrdIOgeIhmKGujbHnybY4uPy2vZXTpZZRm\CC{ZXPyeYl1dWWwdDDv[kB{gW6yaHnsbY4uOSCjZ3fy[YdifGW|IHnueI8h[WepcnXzc41mew>? MW[yN|I5PDh2OB?=
HTK NYjZcJlmTnWwY4Tpc44hSXO|YYm= Mnu0OFAxKG6P MUO3NkBp NInJW4lqdmirYnn0d{BVT0ZvzsNihLNKdmS3Y3XkJG16d2[rYoLvZoxie3RiRHnm[oVz\W62aXH0bY9v MkfpNlMzQDRyMEK=
HTK Ml3NSpVv[3Srb36gRZN{[Xl? MXKxNFAuQDBybl2= NWTpN2RWPzJiaB?= MoLsZoxw[2u|IGTHSk3PuuLCk1nu[JVk\WRiUl;TJIFv\CCKMl:yxsBC[2O3bYXsZZRqd25? Mkn2NlMzQDRyMEK=
Caco-2  MVLGeY5kfGmxbjDBd5NigQ>? MoHaNUDDvU4EoB?= MWGyOEBp M{exNoRm[3KnYYPld{BUTVKWIIDyc5RmcW5iZYjwdoV{e2mxbh?= NVrnZ2NHOjNzOUWwO|A>
HeLa M2jQdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\IOGIyODBibl2= MkfMNlQhcA>? MYrEUXNQ MVjJR|UxKG:oIEGwNI5O MVGyN|E3PTd2OB?=
HeLa M4\DO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnPd4tGPDBibl2= M4HGSVQ5KGh? MkDXSG1UVw>? M4T6WGlEPTBib3[gOFBvVQ>? NGnF[IgzOzF4NUe0PC=>
HeLa M2XZXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXyyNEBvVQ>? NFLqdm44OiCq NU\3OYdMTE2VTx?= NYfOelRkUUN3MDDv[kAzOG6P NH3Ye5gzOzF4NUe0PC=>
HeLa M3f3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rnNVExNzNyL{WwJI5O NFPWdJM4OiCq NVW2RoVnTE2VTx?= MUHpcoNz\WG|ZYOgeIhmKG63bXLldkBw\iCPTWCgLO6V|qivKTDsc5N{KGOnbHzzJIRwe2ViZHXw[Y5l\W62bIm= NVTKPZZLOjNzNkW3OFg>
MDA-MB-231 Mly4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkKxNlUuPDByIH7N MYW0PEBp NIjpZ3RKSzVyIH;mJFI3Oy5{bl5CpC=> MV[yN|A2PTF7OB?=
MCF-7  MorJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XwbVI2NTRyMDDuUS=> NH\rV|Q1QCCq NHrvR4hKSzVyIH;mJFIzOC52bl2= M{jNUVI{ODV3MUm4
ECC-1  NUDLdIJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HyUFExOCCwTR?= NVLsR2o1OjRiaB?= MUTleIhidm:u MVTpcoNz\WG|ZYOgeIhmKHC{b4DvdpRqd25ib3[gZZBweHSxdHnjJI52[2ynaTD0c{A{PSV? NYexU|Z3OjNyMki4NFM>
HEC-1A MkjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITNRmUyODBibl2= NETiZ2wzPCCq M1jzVIV1cGGwb3y= M1jFc4lv[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBieG:ydH;0bYMhdnWlbHXpJJRwKDN7JR?= NI[zfpozOzB{OEiwNy=>
NHAC-kn Mn;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPQNVAwOTByL{WwNEBvVQ>? NIDzVosyOiCq NUi4[YlvTE2VTx?= MkTKTWM2OCCxZjC1NFBvVQ>? NFXiOoUzOzBzN{i3NS=>
A549 M4SwbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1K5RVI2OCCwTR?= MmLJOk04OiCq M2nzOGROW09? NU\MUWN{[2G3c3XzJIEh\3KnYYTldkBqdmirYnn0c5J6KGWoZnXjeEBkd22kaX7lJJdqfGhiVGjUJI9zKGW{bH;0bY5q[g>? MWmyNlk6PDd6MB?=
MG-63 MojlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjrT4Y{ODBibl2= MUWxNkBp MnSxSG1UVw>? NX61N4I5cW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJJRwKDh4JR?= NUXaSoxtOjJ5OUmzN|g>
MG-63 NX\nbJl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrHVVRmOzByIH7N MmXlNlQhcA>? MU\EUXNQ NEDnbm5qdmirYnn0d{B1cGViY3XscEBoem:5dHigeI8hPjdn MWCyNlc6QTN|OB?=
MG-63 NYnMVo85T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\2N|AxKG6P MlK1OFghcA>? MXLEUXNQ NHKzeIxqdmirYnn0d{B1cGViY3XscEBoem:5dHigeI8hPTZn M{DLVVIzPzl7M{O4
HL60  NG\YVW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUmxOVAuOzVyIH7N NVHRU4dwOjRiaB?= M1XR[Ylv[3KnYYPld{Bk\WyuIHHwc5B1d3Orc9Mge4hmdiClb37j[Y51emG2aX;ud{BpcWeqZYKgeIhidiB{NUCgcm0> MWWyNlc2Ozd|OR?=
U937 Mlu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHRNVUxNTN3MDDuUS=> Mn\UNlQhcA>? NIGxOWdqdmO{ZXHz[ZMh[2WubDDhdI9xfG:|aYRCpJdp\W5iY3;uZ4VvfHKjdHnvcpMhcGmpaHXyJJRp[W5iMkWwJI5O NWH4U21wOjJ5NUO3N|k>
SCC-6 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEn5eHIzODBvM{KwNEBvVQ>? M4P2blEzNzJ2L{S4JIg> Mn3uSG1UVw>? NIDocnZqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckBw\iCVQ1OtOkBk\WyuczDpckBiKGSxc3WtJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= NYG3[VR5OjJ3NUKzNlE>
U87  NVnBdFhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXzNVAxNTNyMDDu[y=> NH7uSXkzPCCq NFzDUJZqdmirYnn0d{B1cGViY3XscEBoem:5dHigeI8hPzJnIDDheEAzODCwZx?= NHnkV|IzOjJ5MEi0PS=>
K562 M{i1UGZ2dmO2aX;uJGF{e2G7 MVqxJO69VQ>? M2DhOlEzKGh? MYrEUXNQ MYDlcohidmOnczD0bIUh\XiycnXzd4lwdiCxZjDSWW5ZOyCrbnT1Z4VlKGK7IEWtZZpiNUOmUh?= NFXYfVkzOjF5OUG5PC=>
Reh NYDCVphMTnWwY4Tpc44hSXO|YYm= M4nDUlAvOy9zIN88US=> M2fqU|EzKGh? MYLEUXNQ MmnW[Y5p[W6lZYOgeIhmKGW6cILld5Nqd25ib3[gVnVPYDNiaX7keYNm\CCkeTC1MYF7[S2FZGK= M2TTWVIzOTd7MUm4

... Click to View More Cell Line Experimental Data

In vivo Administration of Trichostatin A at 0.5 mg/kg for 4 weeks displays potent antitumor activity in the N-methyl-N-nitrosourea carcinogen-induced rat mammary carcinoma model, without any measurable toxicity at doses up to 5 mg/kg. [1] Single intraperitoneal doses of 10 mg/kg Trichostatin A in nontransgenic and spinal muscular atrophy (SMA) model mice results in increased levels of acetylated H3 and H4 histones and modest increases in survival motor neuron (SMN) gene expression. Administration of Trichostatin A at 10 mg/kg/day improves survival, attenuates weight loss, and enhances motor behavior in the SMA model mice. [5]

Protocol

Kinase Assay:

[1]

+ Expand

In vitro HDAC activity:

Total cellular extracts are prepared from each breast cancer cell line (MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, or SK-BR-3). A 20 μL crude cell extract (~2.5 ×105 cells), in the presence of varying concentrations of Trichostatin A in 0.1% (v/v) ethanol or 0.1% (v/v) ethanol as vehicle control, are incubated for 60 minutes at 25 °C with 1 μL (~1.5 × 106 cpm) of [3H]acetyl-labeled histone H4 peptide substrate (NH2-terminal residues 2-20) that has been acetylated with [3H]acetic acid, sodium salt (3.7 GBq/mmol) by an in vitro incorporation method. Each 200 μL reaction is quenched with 50 μL of 1 M HCl/0.16 M acetic acid and extracted with 600 μL of ethyl acetate, and released [3H]acetate is quantified by scintillation counting. IC50 values are determined graphically using nonlinear regression to fit inhibition data to the appropriate dose-response curve.
Cell Research:

[1]

+ Expand
  • Cell lines: MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3
  • Concentrations: Dissolved in absolute ethanol, final concentrations ~10 μM
  • Incubation Time: 96 hours
  • Method:

    Cells are exposed to various concentrations of Trichostatin A for 96 hours. After treatment, cell proliferation is estimated using the sulforhodamine B colorimetric assay. Cell viability is determined by trypan blue exclusion.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Inbred virgin female (Ludwig/Wistar/Olac) rats bearing tumors induced with NMU
  • Formulation: Dissolved in DMSO
  • Dosages: ~5 mg/kg/day
  • Administration: Injection s.c.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 23 mg/mL (76.05 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 302.4
Formula

C17H22N2O3

CAS No. 58880-19-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02959905 Recruiting Metastatic Melanoma BGI China|Sun Yat-sen University December 2016 Phase 1
NCT03133819 Enrolling by invitation Diabetes; Neuropathy Polyneuropathy (Manifestation) Chang Gung Memorial Hospital November 2016 Not Applicable
NCT02486965 Recruiting Fibromyalgia University Hospital Brest October 2015 Not Applicable
NCT01954433 Active not recruiting Glenohumeral Arthritis and/or Rotator Cuff Tear Arthropathy (TSA)|Rotator Cuff Tear (RCR)|Trapeziometacarpal Osteoarthritis (TMC OA) Matthias Flury|Winterthur Institute of Health Economics (WIG) Switzerland|Schulthess Klinik November 2013 --
NCT01575106 Completed Pain Massachusetts General Hospital June 2012 Not Applicable
NCT02762903 Completed Osteoarthritis Columbia University August 2009 Not Applicable

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to obtain the enantiomers of TSA, as separate chemicals: R-TSA and S-TSA. Do you have any ideas?

  • Answer:

    Our S1045 Trichostatin A (TSA) is R enantiomer.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Trichostatin A (TSA) | Trichostatin A (TSA) supplier | purchase Trichostatin A (TSA) | Trichostatin A (TSA) cost | Trichostatin A (TSA) manufacturer | order Trichostatin A (TSA) | Trichostatin A (TSA) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID